Omeros stock gains as recent earnings beat estimates and analysts see upside

Published on 09/18/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Omeros stock closed at USD 18.45 on September 17, 2026, after a recent quarterly EPS of USD 0.10 topped forecasts. Analysts see upside with a consensus price target of USD 38.00 and improving earnings expectations into 2027.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros stock (ISIN US6821431029) finished the last completed Nasdaq trading session at USD 18.45 on September 17, 2026, up 6.40 percent from the prior close and trading not far below recent highs in its current range. According to data summarized by MarketBeat on September 17, 2026, this move builds on gains since late August and reflects investor attention on the company’s latest earnings beat and forward expectations.

Recent earnings beat sets the tone

As recent analyst data compiled by Yahoo Finance show, Omeros delivered a notable upside surprise in its latest reported quarter ending June 30, 2026. For that second quarter of 2026, the company posted diluted EPS of USD 0.10, compared with a consensus estimate of a USD 0.33 loss, yielding a positive surprise of USD 0.43 per share and underscoring a sharp swing versus expectations in the period.

The same analyst overview indicates that in the immediately preceding quarter ending March 31, 2026, Omeros recorded EPS of USD 0.57, beating an estimated loss of USD 0.39 by USD 0.96 per share and marking another sizeable earnings surprise. These consecutive beats stand out against the prior year’s pattern: in the quarter ended September 30, 2025, the company’s EPS of USD -0.32 still came in USD 0.16 above the forecast loss of USD 0.48, while the quarter ended December 31, 2025, saw EPS of USD 3.14 versus a consensus of USD 2.24, a USD 0.90 upside.

From a trailing twelve-month perspective, valuation and profitability metrics compiled as of September 17, 2026 by Yahoo Finance indicate that Omeros generated revenue of USD 38.42 million and net income attributable to common shareholders of USD 116.53 million over the last four reported quarters, translating into diluted EPS of USD 1.65 and a profit margin of 324.88 percent on that trailing basis. While such margins in small-cap biotech can be influenced by one-off items, the combination of positive EPS and recent quarterly beats gives investors a more constructive earnings backdrop to weigh alongside the company’s pipeline risks.

Analyst consensus suggests room for further gains

Analyst coverage remains a key reference point for Omeros stock at the current level. According to the rating and target-price summary presented by MarketBeat on September 17, 2026, Omeros carries an average rating score of 2.67 on a scale where lower numbers indicate more bullish stances, derived from 1 strong buy, 2 buy and 3 hold recommendations and no sell ratings. The same overview reports a consensus price target of USD 38.00, implying approximately 105.6 percent upside from the recent reference price around USD 18.48 and signaling that covering analysts broadly expect further appreciation if the company can sustain its earnings trajectory.

Forward estimates compiled by Yahoo Finance on September 17, 2026 show that the consensus view among two to three analysts foresees EPS of USD -0.03 for the current quarter ending September 30, 2026 and USD 0.05 for the quarter ending December 31, 2026, alongside expected full-year 2026 EPS of USD 0.66 and 2027 EPS of USD 1.14. On the revenue side, these estimates point to about USD 36.7 million for the current quarter, USD 50.5 million for the next quarter and USD 125.6 million for all of 2026, rising to USD 197.8 million in 2027, suggesting that analysts anticipate both top-line growth and a gradual strengthening of earnings power over the next several reporting periods.

Valuation measures in the same key-statistics snapshot from Yahoo Finance as of September 17, 2026 imply a trailing price-to-earnings ratio of 10.50 for Omeros based on its recent share price and diluted EPS of 1.65, and a forward P/E of 71.94 on near-term consensus figures. For investors, this mix of low trailing and higher forward multiples can reflect expectations that some of the recent earnings strength has come from non-recurring factors, while the core operations are still transitioning toward more stable profitability.

Risks and market context for Omeros stock

The broader market backdrop has also supported risk assets around mid-September 2026, providing a constructive environment for smaller healthcare names like Omeros. A recent US market recap cited by Yahoo Finance on September 17, 2026 noted that major indices advanced as Treasury yields and oil prices eased, with technology and growth stocks helping recover ground lost after the latest Federal Reserve rate decision. In such an environment, positive surprises from individual companies can attract incremental capital as investors look for earnings-backed stories rather than purely speculative momentum.

Despite the upbeat elements in the latest numbers, Omeros remains exposed to typical biotechnology-sector risks. The profitability snapshot from Yahoo Finance shows an operating margin of just 0.26 percent on a trailing basis and a negative return on assets of -18.68 percent, alongside EBITDA of USD -71.91 million and operating cash flow of USD -68.67 million over the same twelve-month span. These figures highlight that, even with headline net income positive over the period, the underlying business still burns cash and relies on future commercialization milestones, partnerships or financings to sustain and grow its pipeline.

Stock level and key figures for investors

Per the latest closing data on September 17, 2026, Omeros stock closed at USD 18.45 on the Nasdaq, up USD 1.11 or 6.40 percent from the prior day’s finish, with an extended session indication around USD 18.47 later that afternoon, according to price information referenced by Yahoo Finance. The same data set places Omeros’s market capitalization near USD 1.26 billion as of that date, giving investors a sense of the company’s current size within the Nasdaq biotechnology universe.